Denotes maximum number of antisense oligonucleotides under the collaborative arrangements.

No definition available.

Name:	camp_CollaborativeArrangementMaximumNumberOfAntisenseOligonucleotides
Namespace Prefix:	camp_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of reduction in research and development expense under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	camp_CollaborativeArrangementReductionInResearchAndDevelopmentExpense
Namespace Prefix:	camp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 912
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478345/912-310-45-2

+ Details

Name:	us-gaap_UnbilledContractsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=camp_EliLillyAndCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Eli Lilly and Company (Details) - Eli Lilly and Company - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2023 antisenseOligonucleotide	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Collaboration and License Agreements
Maximum number of antisense oligonucleotides \| antisenseOligonucleotide	3
Reduction in R&D expense		$ 0.0	$ 0.0	$ 0.1	$ 0.3
Maximum
Collaboration and License Agreements
Unbilled receivable (less than)						$ 0.1